BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

BridgeBio Pharma has disclosed Restructuring Costs across 4 years of filings, most recently posting $11.1 million for Q4 2025.

• Restructuring Costs for Q4 2025 came in at $11.1 million, up 137.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.7 million (up 69.03% YoY), and the FY2025 annual result was $21.3 million, up 36.8% from the prior year.
• Restructuring Costs came in at $11.1 million for Q4 2025 at BridgeBio Pharma, up from $8.8 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $22.7 million in Q1 2022 to a low of $272000.0 in Q3 2023.
• The 4-year median for Restructuring Costs is $4.1 million (2023), against an average of $5.4 million.
• Across the five-year window, Restructuring Costs tumbled 94.58% in 2023 and jumped 1598.9% in 2024, its largest moves.
• BridgeBio Pharma's Restructuring Costs stood at $7.7 million in 2022, then plunged by 90.2% to $754000.0 in 2023, then jumped by 522.41% to $4.7 million in 2024, then surged by 137.18% to $11.1 million in 2025.
• The last three Restructuring Costs figures came in at $11.1 million (Q4 2025), $8.8 million (Q3 2025), and $712000.0 (Q2 2025), per Business Quant data.